Journal of Clinical Oncology, Vol 17, Issue 1
(January), 1999: 150
© 1999 American Society for Clinical Oncology
Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
M. Van Glabbeke,
A.T. van Oosterom,
J.W. Oosterhuis,
H. Mouridsen,
D. Crowther,
R. Somers,
J. Verweij,
A. Santoro,
J. Buesa,
T. Tursz
From the European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium; Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium; Rotterdam Cancer Institute, Rotterdam, the Netherlands; Righospitalet, Copenhagen, Denmark; Christie Hospital, Manchester, United Kingdom; Antoni van Leeuwenhoekhuis, Amsterdam, the Netherlands; Istituto Tumori, Milan, Italy; Hospital General de Asturias, Oviedo, Spain; and Institut Gustave Roussy, Villejuif, France.
Address reprint requests to Martine Van Glabbeke, EORTC Data Center, avenue Mounier 83, bte 11, 1200 Bruxelles, Belgium; Email mvg{at}eortc.be
PURPOSE: A total of 2,185 patients with advanced soft tissue sarcomas who had been treated in seven clinical trials investigating the use of doxorubicin- or epirubicin-containing regimens as first-line chemotherapy were studied in this prognostic-factor analysis.
PATIENTS AND METHODS: Overall survival time (median, 51 weeks) and response to chemotherapy (26% complete response or partial response) were the two end points. The cofactors were sex; age; performance status; prior therapies; the presence of locoregional or recurrent disease; lung, liver, and bone metastases at the time of entry onto the trial; long time period between the initial diagnosis of sarcoma and entry onto the study; and histologic type and grade.
RESULTS: Univariate analyses showed (a) a significant, favorable influence of good performance status, young age, and absence of liver metastases on both survival time and response rate, (b) a significant, favorable influence of low histopathologic disease grade on survival time, despite a significantly lower response rate, (c) increased survival time for patients with a long time period between the initial diagnosis of sarcoma and entry onto the study, despite equivalent response rates, and (d) increased survival time with liposarcoma or synovial sarcoma, a decreased survival time with malignant fibrous histiocytoma, a lower response rate with leiomyosarcoma, and a higher response rate with liposarcoma (P < .05 for all log-rank and  2 tests). The Cox model selected good performance status (P < .0001), absence of liver metastases (P = .0001), low histopathologic grade (P = .0002), long time lapse since initial diagnosis (P = .0004), and young age (P = .0045) as favorable prognostic factors of survival time. The logistic model selected absence of liver metastases (P < .0001), young age (P = .0024), high histopathologic grade (P = .0051), and liposarcoma (P = .0065) as favorable prognostic factors of response rate.
CONCLUSION: This analysis demonstrates that for advanced soft tissue sarcoma, response to chemotherapy is not predicted by the same factors as is overall survival time. This needs to be taken into account in the interpretation of trials assessing the value of new agents for this disease on the basis of response to treatment.
The studies that form the basis of this work were supported by the Prix Pierre Bardoux.
This article has been cited by other articles:
|
|
|
|
 
N. Penel, B. N. Bui, J.-O. Bay, D. Cupissol, I. Ray-Coquard, S. Piperno-Neumann, P. Kerbrat, C. Fournier, S. Taieb, M. Jimenez, et al.
Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study
J. Clin. Oncol.,
November 10, 2008;
26(32):
5269 - 5274.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Ray-Coquard, A. Le Cesne, J. S. Whelan, P. Schoffski, B. N. Bui, J. Verweij, S. Marreaud, M. van Glabbeke, P. Hogendoorn, and J.-Y. Blay
A Phase II Study of Gefitinib for Patients with Advanced HER-1 Expressing Synovial Sarcoma Refractory to Doxorubicin-Containing Regimens
Oncologist,
April 1, 2008;
13(4):
467 - 473.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hajitou, D. C. Lev, J. A. F. Hannay, B. Korchin, F. I. Staquicini, S. Soghomonyan, M. M. Alauddin, R. S. Benjamin, R. E. Pollock, J. G. Gelovani, et al.
A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging
PNAS,
March 18, 2008;
105(11):
4471 - 4476.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Sternheim, X. Jin, B. Shmookler, J. Jelinek, and M. M. Malawer
'Telangiectatic' Transformation in Soft Tissue Sarcomas. A Clinicopathology Analysis of an Aggressive Feature of High-grade Sarcomas
Ann. Surg. Oncol.,
January 1, 2008;
15(1):
345 - 354.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Fayette, E. Martin, S. Piperno-Neumann, A. Le Cesne, C. Robert, S. Bonvalot, D. Ranchere, P. Pouillart, J. M. Coindre, and J. Y. Blay
Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases
Ann. Onc.,
December 1, 2007;
18(12):
2030 - 2036.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Tascilar, W. J. Loos, C. Seynaeve, J. Verweij, and S. Sleijfer
The Pharmacologic Basis of Ifosfamide Use in Adult Patients with Advanced Soft Tissue Sarcomas
Oncologist,
November 1, 2007;
12(11):
1351 - 1360.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. G. Maki, J. K. Wathen, S. R. Patel, D. A. Priebat, S. H. Okuno, B. Samuels, M. Fanucchi, D. C. Harmon, S. M. Schuetze, D. Reinke, et al.
Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002
J. Clin. Oncol.,
July 1, 2007;
25(19):
2755 - 2763.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Pawlik, J.-N. Vauthey, E. K. Abdalla, R. E. Pollock, L. M. Ellis, and S. A. Curley
Results of a Single-Center Experience With Resection and Ablation for Sarcoma Metastatic to the Liver
Arch Surg,
June 1, 2006;
141(6):
537 - 544.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Theou, S. Gil, A. Devocelle, C. Julie, A. Lavergne-Slove, A. Beauchet, P. Callard, R. Farinotti, A. Le Cesne, A. Lemoine, et al.
Multidrug Resistance Proteins in Gastrointestinal Stromal Tumors: Site-Dependent Expression and Initial Response to Imatinib
Clin. Cancer Res.,
November 1, 2005;
11(21):
7593 - 7598.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sleijfer, C. Seynaeve, and J. Verweij
Using Single-Agent Therapy in Adult Patients with Advanced Soft Tissue Sarcoma Can Still Be Considered Standard Care
Oncologist,
November 1, 2005;
10(10):
833 - 841.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Garcia-Carbonero, J.G. Supko, R.G. Maki, J. Manola, D.P. Ryan, D. Harmon, T.A. Puchalski, G. Goss, M.V. Seiden, A. Waxman, et al.
Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study
J. Clin. Oncol.,
August 20, 2005;
23(24):
5484 - 5492.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Clark, C. Fisher, I. Judson, and J. M. Thomas
Soft-Tissue Sarcomas in Adults
N. Engl. J. Med.,
August 18, 2005;
353(7):
701 - 711.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Pappo, M. Devidas, J. Jenkins, B. Rao, R. Marcus, P. Thomas, M. Gebhardt, C. Pratt, and H. E. Grier
Phase II Trial of Neoadjuvant Vincristine, Ifosfamide, and Doxorubicin With Granulocyte Colony-Stimulating Factor Support in Children and Adolescents With Advanced-Stage Nonrhabdomyosarcomatous Soft Tissue Sarcomas: A Pediatric Oncology Group Study
J. Clin. Oncol.,
June 20, 2005;
23(18):
4031 - 4038.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. H. Baker
Medical and Pediatric Oncology, Not Adult and Pediatric Oncology
J. Clin. Oncol.,
June 20, 2005;
23(18):
4003 - 4005.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. L. Spurrell, C. Fisher, J. M. Thomas, and I. R. Judson
Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital
Ann. Onc.,
March 1, 2005;
16(3):
437 - 444.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Le Cesne, J.Y. Blay, I. Judson, A. Van Oosterom, J. Verweij, J. Radford, P. Lorigan, S. Rodenhuis, I. Ray-Coquard, S. Bonvalot, et al.
Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial
J. Clin. Oncol.,
January 20, 2005;
23(3):
576 - 584.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. S. P. van Rijswijk, M. J. A. Geirnaerdt, P. C. W. Hogendoorn, A. H. M. Taminiau, F. van Coevorden, A. H. Zwinderman, T. L. Pope, and J. L. Bloem
Soft-Tissue Tumors: Value of Static and Dynamic Gadopentetate Dimeglumine-enhanced MR Imaging in Prediction of Malignancy
Radiology,
November 1, 2004;
233(2):
493 - 502.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. V. Heymach, J. Desai, J. Manola, D. W. Davis, D. J. McConkey, D. Harmon, D. P. Ryan, G. Goss, T. Quigley, A. D. Van den Abbeele, et al.
Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas
Clin. Cancer Res.,
September 1, 2004;
10(17):
5732 - 5740.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. A. Porter, S. B. Cantor, G. L. Walsh, V. W. Rusch, D. H. Leung, A. Y. DeJesus, R. E. Pollock, M. F. Brennan, and P. W. T. Pisters
Cost-effectiveness of pulmonary resection and systemic chemotherapy in the management of metastatic soft tissue sarcoma: A combined analysis from the University of Texas M. D. Anderson and Memorial Sloan-Kettering Cancer Centers
J. Thorac. Cardiovasc. Surg.,
May 1, 2004;
127(5):
1366 - 1372.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Garcia-Carbonero, J.G. Supko, J. Manola, M.V. Seiden, D. Harmon, D.P. Ryan, M.T. Quigley, P. Merriam, J. Canniff, G. Goss, et al.
Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy
J. Clin. Oncol.,
April 15, 2004;
22(8):
1480 - 1490.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Yovine, M. Riofrio, J.Y. Blay, E. Brain, J. Alexandre, C. Kahatt, A. Taamma, J. Jimeno, C. Martin, Y. Salhi, et al.
Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma Patients
J. Clin. Oncol.,
March 1, 2004;
22(5):
890 - 899.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Cormier and R. E. Pollock
Soft Tissue Sarcomas
CA Cancer J Clin,
March 1, 2004;
54(2):
94 - 109.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Colwell, J. D'Cunha, S. O. Vargas, B. Parker, P. D. Cin, and M. A. Maddaus
Synovial sarcoma of the pleura: A clinical and pathologic study of three cases
J. Thorac. Cardiovasc. Surg.,
October 1, 2002;
124(4):
828 - 832.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Spunt, D. A. Hill, A. M. Motosue, C. A. Billups, A. M. Cain, B. N. Rao, C. B. Pratt, T. E. Merchant, and A. S. Pappo
Clinical Features and Outcome of Initially Unresected Nonmetastatic Pediatric Nonrhabdomyosarcoma Soft Tissue Sarcoma
J. Clin. Oncol.,
August 1, 2002;
20(15):
3225 - 3235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Lopez, P. Vici, L. Di Lauro, and S. Carpano
Increasing Single Epirubicin Doses in Advanced Soft Tissue Sarcomas
J. Clin. Oncol.,
March 1, 2002;
20(5):
1329 - 1334.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. H. C. Bramwell, D. Morris, D. S. Ernst, I. Hings, M. Blackstein, P. M. Venner, E. I. Ette, M. W. Harding, A. Waxman, and G. D. Demetri
Safety and Efficacy of the Multidrug-Resistance Inhibitor Biricodar (VX-710) with Concurrent Doxorubicin in Patients with Anthracycline-resistant Advanced Soft Tissue Sarcoma
Clin. Cancer Res.,
February 1, 2002;
8(2):
383 - 393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Delaloge, A. Yovine, A. Taamma, M. Riofrio, E. Brain, E. Raymond, P. Cottu, F. Goldwasser, J. Jimeno, J. L. Misset, et al.
Ecteinascidin-743: A Marine-Derived Compound in Advanced, Pretreated Sarcoma Patients--Preliminary Evidence of Activity
J. Clin. Oncol.,
March 1, 2001;
19(5):
1248 - 1255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Spillane, R. A'Hern, I. R. Judson, C. Fisher, and J. M. Thomas
Synovial Sarcoma: A Clinicopathologic, Staging, and Prognostic Assessment
J. Clin. Oncol.,
November 15, 2000;
18(22):
3794 - 3803.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J-Y. Blay, D. Bouhour, I. Ray-Coquard, C. Dumontet, T. Philip, and P. Biron
High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Transplantation for Advanced Soft Tissue Sarcoma in Adults
J. Clin. Oncol.,
November 1, 2000;
18(21):
3643 - 3650.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. E. C. Plaat, H. Hollema, W. M. Molenaar, G. H. T. Broers, J. Pijpe, M. F. Mastik, H. J. Hoekstra, E. van den Berg, R. J. Scheper, and W. T. A. van der Graaf
Soft Tissue Leiomyosarcomas and Malignant Gastrointestinal Stromal Tumors: Differences in Clinical Outcome and Expression of Multidrug Resistance Proteins
J. Clin. Oncol.,
September 18, 2000;
18(18):
3211 - 3220.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Le Cesne, I. Judson, D. Crowther, S. Rodenhuis, H. J. Keizer, Q. Van Hoesel, J. Y. Blay, J. Frisch, M. Van Glabbeke, C. Hermans, et al.
Randomized Phase III Study Comparing Conventional-Dose Doxorubicin Plus Ifosfamide Versus High-Dose Doxorubicin Plus Ifosfamide Plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Advanced Soft Tissue Sarcomas: A Trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group
J. Clin. Oncol.,
July 14, 2000;
18(14):
2676 - 2684.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Verweij, S. M. Lee, W. Ruka, J. Buesa, R. Coleman, R. van Hoessel, C. Seynaeve, E. D. di Paola, M. van Glabbeke, D. Tonelli, et al.
Randomized Phase II Study of Docetaxel Versus Doxorubicin in First- and Second-Line Chemotherapy for Locally Advanced or Metastatic Soft Tissue Sarcomas in Adults: A Study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
J. Clin. Oncol.,
May 10, 2000;
18(10):
2081 - 2086.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
